INTRODUCTION {#s1}
============

Prostate-specific antigen (PSA), also known as human kallikrein 3, has been widely used for early detection of prostate cancer as well as monitoring of its treatment. However, nonmalignant conditions, especially benign prostate hyperplasia and acute prostatitis, often raise serum PSA, which complicates the diagnosis of prostate cancer using PSA measurement alone \[[@R1], [@R2]\].

Since its identification, various retrospective and prospective studies have assessed the usefulness of free/total (F/T) PSA ratio (cut-off points of 0.1--0.2) for differentiating between benign conditions and prostate cancer, especially in "gray-zone" patients who have PSA levels of 4--10 ng/ml \[[@R2]--[@R4]\]. Attempts have also been made to identify biomarkers that predict prostate cancer and its prognosis, but these often require quantitative PCR or immunohistochemical analysis. Therefore, additional biomarkers for prostate cancer whose values can be determined more simply and less expensively are needed.

Neutrophil-to-lymphocyte ratio (NLR) can be easily calculated from routine complete blood counts (CBCs) in peripheral blood. NLR has been suggested as not only a predictor of systemic inflammatory response in critical care patients but also a prognosticator for some solid malignancies including prostate cancer \[[@R5]--[@R14]\]. Men with elevated serum PSA yet without the diagnosis of prostate cancer were found to have a higher NLR compared with those with a normal PSA level \[[@R15]\], suggesting that certain markers of systemic inflammation and/or immune system activation were associated with an elevated serum PSA. The roles of NLR in monitoring of advanced prostate cancer such as castration-resistant tumors or that in patients who received docetaxel-based chemotherapy \[[@R15]-- [@R17]\], but not in initial diagnosis of prostate cancer, have been investigated. In the present study, we aim to assess the usefulness of NLR as a biomarker in men undergoing prostate needle biopsy. To our knowledge, this is the first study to evaluate NLR as a predictor of prostate cancer diagnosis.

MATERIALS and METHODS {#s2}
=====================

Patients {#s2_1}
--------

A total of 73,637 CBC exams including absolute neutrophil and lymphocyte counts were performed in 9,782 men at the Department of Urology, Yokohama City University Hospital (Yokohama, Japan) from 1999 to 2015. Of these, 3,011 men had both CBCs and F/T PSA ratio. We further investigated 810 men who underwent prostate needle biopsy while showing PSA levels between 4 and 10 ng/mL \[Fig [1](#F1){ref-type="fig"}\]. Patients\' age, NLR, PSA, and F/T PSA ratio are summarized in Table [1](#T1){ref-type="table"}. The institutional review board of Yokohama City University approved this study.
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###### Patients\' characteristics

  Variables       median (range, mean ± SD)
  --------------- --------------------------------
  Age (years)     73 (38--94, 73.4 ± 8.1)
  NLR             1.94 (0.51--9.80, 2,14 ± 1.05)
  PSA (ng/mL)     6.33 (4.0--10.0, 6,58 ± 1.60)
  F/T PSA ratio   0.18 (0.04--0.74, 0.18 ± 0.07)

Clinical and laboratory assessments {#s2_2}
-----------------------------------

NLR was calculated using neutrophil and lymphocyte counts via CBCs obtained simultaneously with PSA and its F/T ratio. Prostate needle biopsy was typically performed within 4 weeks of blood tests. In some cases, prostate needle biopsy was not performed due to, for instance, the presence of urinary tract infection such as acute prostatitis, unsuspicious findings in pre-biopsy MRI, or advanced ages. We determined the cut-off point of NLR according to the sensitivity and specificity levels derived from area under receiver operator characteristics (AUROC) curve plotted using the presence or absence of prostatic carcinoma.

Statistical analyses {#s2_3}
--------------------

Patients\' characteristics and preoperative factors were analyzed using Mann-Whitney *U* test and chi-square test, using Graph Pad Prism (Graph Pad Software, La Jolla, CA, USA). Statistical significance was determined as *p* \< 0.05.

RESULTS {#s3}
=======

NLR values and PSA {#s3_1}
------------------

There was no statistically significant difference (*p* = 0.242) in NLR value among men with PSA of \< 4 ng/mL (median/mean ± SD: 2.05/2.45 ± 2.04), PSA between 4 and 10 (2.00/2.33 ± 1.63), and PSA of \> 10 but \< 20 (2.11/2.45 ± 1.84) \[Fig [2](#F2){ref-type="fig"}\]. Nonetheless, NLR was significantly (*p* \< 0.001) higher in men whose PSA was \> 20 (2.52/3.63 ± 4.20), compared with those with PSA of ≤ 20 (2.03/2.44 ± 2.05). NLR values were next assessed in men with a PSA level of 4--20. For this analysis, we first used the institutional cut-off point (0.15) of F/T PSA ratio in our clinics. NLR was found to be significantly (*p* \< 0.001) higher in those with F/T PSA ratio of \<0.15 (median/mean ± SD: 2.03/2.39 ± 1.78) than in those with F/T PSA ratio of ≥ 0.15 (1.90/2.21 ± 1.28).
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NLR values in men with vs. without prostate cancer {#s3_2}
--------------------------------------------------

We further compared NLRs in 810 men undergoing prostate biopsy. Of these, 357 (44.1%) were positive for prostatic carcinoma. None of these patients were found to have metastatic disease at the time of the biopsy. Gleason score (GS) was available in 344 of 357 patients: 5 (1.4%) GS5, 105 (30.5%) GS6, 163 (47.4%) GS7, 45 (13.1%) GS8, 21 (6.1%) GS9, and 5 (1.4%) GS10. NLR was again significantly (*p* \< 0.001) higher in men in whom prostate cancer was found (median/mean ± SD: 2.02/2.33 ± 1.21) than in those without prostate cancer (1.84/2.00 ± 0.88) \[Fig [3](#F3){ref-type="fig"}\]. However, there were no significant correlations between NLR value and GS \[Fig [4](#F4){ref-type="fig"}\].
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Based on the AUROC curve, NLR cut-off point was determined as 2.40 to predict prostate cancer \[Fig [5](#F5){ref-type="fig"}\]. Multivariate analysis showed that age (*HR* = 1.91), NLR (*HR* = 2.21), PSA (*HR* = 1.54), and F/T PSA ratio (*HR* = 3.13) were independent risk factors to predict prostate cancer (Table [2](#T2){ref-type="table"}). Positive and negative predictive values, using the NLR cut-off point, were 56.6% and 60.8%, respectively (Table [3](#T3){ref-type="table"}). When NLR was combined with F/T PSA ratio less than 0.15, positive and negative predictive values became 80.7% and 60.1%, respectively. When F/T PSA ratios of less than 0.12 and 0.19 were used as cut-off points, in combination with NLR, positive predictive values were 83.3% and 72.9% and negative predictive values were 40.6% and 62.1%, respectively.
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###### Univariate and multivariate analyses for predicting prostate cancer

                        Univariate analysis   Multivariate analysis                                   
  --------------- ----- --------------------- ----------------------- ----------- ------ ------------ -----------
                  *n*   HR                    95% CI                  *p* value   HR     95% CI       *p* value
  Age (yr)                                                            \<0.001                         \<0.001
   \<71           384   1                                                         1                   
   ≥71            426   1.80                  1.34--2.42                          1.91   1.38--2.63   
  NLR                                                                 \<0.001                         \<0.001
   \<2.40         228   1                                                         1                   
   ≥2.40          582   2.02                  1.48--2.76                          2.21   1.5603.13    
  PSA (ng/mL)                                                         \<0.001                         0.010
   \<5.72         297   1                                                         1                   
   ≥5.72          513   1.85                  1.38--2.48                          1.54   1.11--2.14   
  F/T PSA ratio                                                       \<0.001                         \<0.001
   \<0.15         509   2.73                  2.03--3.66                          3.13   2.26--4.34   
   ≥0.15          301   1                                                         1                   

###### Prediction of prostate cancer using NLR and F/T PSA ratio

                                     Sensitivity          Specificity          PPV                  NPV
  ---------------------------------- -------------------- -------------------- -------------------- --------------------
  F/T PSA ratio \<0.12               23.8% (85 of 357)    88.7% (402 of 453)   62.5% (85 of 136)    59.5 (402 of 676)
  F/T PSA ratio \<0.15               50.1% (179 of 357)   73.1% (331 of 453)   59.5% (179 of 301)   65.0% (331 of 509)
  F/T PSA ratio \<0.19               75.4% (269 of 357)   49.7% (225 of 453)   54.1% (269 of 497)   71.2% (225 of 313)
  NLR ≥2.40                          36.1% (129 of 357)   78.1% (354 of 453)   56.6% (129 of 228)   60.8% (354 of 582)
  NLR ≥2.40 & F/T PSA ratio \<0.12   9.5% (34 of 357)     98.2% (445 of 453)   83.3% (35 of 42)     40.6% (312 of 768)
  NLR ≥2.40 & F/T PSA ratio \<0.15   18.8% (67 of 357)    96.5% (437 of 453)   80.7% (67 of 83)     60.1% (347 of 727)
  NLR ≥2.40 & F/T PSA ratio \<0.19   29.4% (105 of 357)   91.4% (414 of 453)   72.9% (105 of 144)   62.1% (414 of 666)

PPV: positive predictive value, NPV: negative predictive value

DISCUSSION {#s4}
==========

This is the first study to evaluate NLR to predict prostate cancer and reveals that higher NLR correlates with the higher incidence of prostate cancer even in men with similar PSA levels. There is increasing evidence correlating the presence of systemic inflammation with poorer cancer-specific survival in patients with several solid tumors, such as colorectal carcinoma \[[@R6], [@R18]--[@R23]\]. Moreover, nonsteroidal anti-inflammatory medications have been suggested to reduce the risk of developing prostate cancer, implying a critical correlation between inflammation and prostate carcinogenesis \[[@R18], [@R19]\]. It has previously been demonstrated that the presence of an inflammatory response can be determined by both the expression of C-reactive protein and/or an elevation in NLR \[[@R6], [@R24], [@R25]\]. In particular, the latter has been shown to be associated with poorer prognosis in patients with prostate cancer \[[@R15]\].

Although PSA has a good sensitivity, the test suffers from low specificity due to the difficulty in distinguishing patients with prostate cancer versus benign prostatic conditions \[[@R2], [@R26]\]. Other data show that men with a false positive PSA at screening are more likely to develop prostate cancer during the follow-up \[[@R27], [@R28]\]. To further improve the ability to predict prostate cancer, additional markers, including F/T PSA ratio, have been used. Despite the various cut-off levels defined in different studies, ideal cut-off values for F/T PSA ratio have not yet been determined \[[@R2], [@R29], [@R30]\]. Furthermore, an invasive biopsy may miss cancer in some men, given up to 20% of men will be found to have prostate cancer on a repeated biopsy \[[@R27], [@R31]\]. NLR was shown to positively correlate with elevated serum PSA \[[@R27]\]. The current study confirmed the findings and further showed that NLR with or without F/T PSA ratio contributed greatly to the prediction of positive and negative prostate biopsies. Accordingly, NLR either alone or in combination with F/T PSA ratio may function as a new biomarker in men who are considered to undergo prostate needle biopsy. We additionally assessed the usefulness of combinations of the factors, including age, PSA, F/T PSA ratio, and NLR. However, the sensitivities and specificities of the combinations were not superior to those of NLR or NLR + F/T PSA ratio. Based on the AUROC, the NLR cut-off value was determined as 2.40. In several studies analyzing advanced pancreatic cancer, the NLR cut-off points were around 5 \[[@R32]\]. In intrahepatic cholangiocarcinoma and liver metastasis from colorectal carcinoma, the NLR cut-off value was also set as 5 \[[@R27]\]. In renal cell carcinoma, it was 2 to 5, which varied in different studies \[[@R27]\].

The interactions between tumor and host immune system promote tumor cell proliferation and metastasis as well as activate the inflammatory cascade in the host, which further deteriorates the general condition of cancer patients \[[@R33]\]. Some studies proposed that tumor-associated neutrophils had two different states as anti-tumorigenic (N1-phenotype) and pro-tumorigenic (N2-phenotype) factors \[[@R34], [@R35]\].

Immunohistochemistry was performed to detect CD66b-positive neutrophils and CD8-positive lymphocytes in radical prostatectomy specimens (unpublished data). However, there was no statistically significant difference in the number of infiltrating CD66b-positive or CD8-positive cells between normal-appearing prostate and prostate cancer. No significant correlations between neutrophil number, lymphocyte number, or their ratio versus tumor characteristics (e.g. GS, pathological stage) or patient outcome were also seen. Further immunohistochemical analysis, especially in prostate biopsy specimens, may thus be required. There has been an immunohistochemical study in esophageal squamous cell carcinoma specimens, which demonstrated intratumoral neutrophils, CD8-positive lymphocytes, and their ratio, as seen in NLR in CBCs, correlated with disease progression \[[@R27]\]. However, no attempts in other tissue specimens have been made to determine the role of NLR in tumorigenesis or tumor progression as a biomarker.

There are limitations as a retrospective study. Because we extracted the data electrically, the detailed information about the criteria for performing prostate needle biopsy was unconfirmed. Therefore, there might be a bias to select patients who underwent the biopsy. Importantly, we assessed the role of NLR as a predictor of prostate cancer only in men who had a PSA value of 4--10 and underwent prostate biopsy. It is also possible that the initial prostate biopsy failed to identify existing adenocarcinoma in a subset of patients.

In conclusion, our data indicate that NLR functions as a biomarker to predict prostate cancer in men who undergo prostate needle biopsy. Combination of NLR with F/T PSA ratio likely increases both positive predictive value and negative predictive value of prostate needle biopsy.
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